Partial
Partially Aligned
Patient Risk:
Low
Summary
Two of three claims are supported by the provided FDA label excerpts. The approval-date claim is not supported by the provided label sections, so overall alignment is partial.
Category Scores
Accurate Statements
Tymlos is an injectable osteoporosis treatment.
Supported indirectly by label excerpts stating TYMLOS is a subcutaneous injection and indicated for osteoporosis (Sections 1.1/1.2 and 2.1 Dosage form not explicitly labeled here but route is provided in 2.1).
Tymlos is indicated to increase bone mass in people at high risk for fracture.
Supported for increasing bone density in men with osteoporosis at high risk for fracture (Section 1.2) and increased bone mass concept aligns with the label's bone density/bone mass outcomes; high risk for fracture definition and indication basis are provided in Sections 1.1/1.2.
Unsupported Statements
Tymlos (abaloparatide) was approved by the U.S. FDA on April 28, 2017.
The provided FDA label excerpts do not include FDA approval date information; therefore this claim is not supported by the supplied prescribing information.
Contradictions
Important Omissions
The AI response does not specify the full indicated populations/criteria (e.g., postmenopausal women vs men; definition of 'high risk for fracture' including history of osteoporotic fracture, multiple risk factors, or failure/intolerance to other therapy).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported item is an approval-date claim, which does not directly change dosing/safety. The indication statement is largely aligned but is not fully specific to label-defined criteria.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Approval date claim is not supported by the provided label excerpts.
Suggested Improvement
Remove or qualify the approval-date statement, and align indication wording more precisely to label-defined populations and 'high risk for fracture' criteria (including postmenopausal women vs men and the failure/intolerance definition where applicable).